Isis Pharmaceuticals Inc. shares (NASDAQ:ISIS) extended a slow recovery Wednesday as investors took note of phase II data showing that the company's experimental antisense drug, ISIS-GCGRRx, helped patients with type 2 diabetes improve control of the disease, even when they're unable to do so with metformin.